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Abstract
Background: Financial conflicts of interest (fCOI) can introduce actions that bias clinical trial results and reduce
their objectivity. We obtained information from investigators about adherence to practices that minimize the
introduction of such bias in their clinical trials experience.
Methods: Email survey of clinical trial investigators from Canadian sites to learn about adherence to practices that
help maintain research independence across all stages of trial preparation, conduct, and dissemination. The main
outcome was the proportion of investigators that reported full adherence to preferred trial practices for all of their
trials conducted from 2001-2006, stratified by funding source.
Results: 844 investigators responded (76%) and 732 (66%) provided useful information. Full adherence to preferred
clinical trial practices was highest for institutional review of signed contracts and budgets (82% and 75% of
investigators respectively). Lower rates of full adherence were reported for the other two practices in the trial
preparation stage (avoidance of confidentiality clauses, 12%; trial registration after 2005, 39%). Lower rates of full
adherence were reported for 7 practices in the trial conduct (35% to 43%) and dissemination (53% to 64%) stages,
particularly in industry funded trials. 269 investigators personally experienced (n = 85) or witnessed (n = 236) a
fCOI; over 70% of these situations related to industry trials.
Conclusion: Full adherence to practices designed to promote the objectivity of research varied across trial stages
and was low overall, particularly for industry funded trials.
Background
An estimated 20,000 trials are initiated internationally
each year [1] with over 500 published each month [2].
Participants volunteer for these trials under the assump-
tion that their efforts will contribute to the advancement
of science. Accordingly, study results need to be objec-
tive, publicly available, and responsibly applied to
advance knowledge and healthcare practice.
Concern about the potential impact of financial con-
flicts of interest (fCOI) on research conduct has led to
recommendations for clinical trial practices designed to
maintain an investigator’s independence and to avoid
the introduction of bias and suppression of results.
Practices that promote the objectivity of research have
been outlined in national standards for research ethics
boards [3-6], requirements for federally funded research
[3,7] guidance for academic institutions [8,9], require-
ments for trial registration [10] and for manuscripts
submitted to biomedical journals [11-13]. We know lit-
tle about adherence to these practices in the conduct of
clinical trials.
We surveyed investigators about their experiences
with practices designed to ensure the objectivity of
research across all stages of industry and non-industry
funded trials.
Methods
Survey Participants and Data Collection
We identified investigators conducting clinical trials at
Canadian sites using the meta-register of Controlled
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Standard Randomized Controlled Trial Number
(ISRCTN) or Clinicaltrials.gov. E-mail addresses were
obtained from the trial registry record or, if unavailable,
from an internet search of public sources. Our study
was approved by the research ethics board at the Baycr-
est Centre affiliated with the University of Toronto.
We identified 1,127 unique investigators based in
Canada with a valid e-mail address. From May through
N o v e m b e r ,2 0 0 6 ,w ee - m a i l e dp o t e n t i a lr e s p o n d e n t s ,
asking them to complete an online questionnaire. A five
dollar gift card was offered upon completion. Consent
was considered to be implied when the investigators
completed the on-line survey. Investigators were told
that results will be presented as aggregate data only.
Non-responders and those completing only a small por-
t i o no ft h eq u e s t i o n n a i r ew e r es e n tu pt of i v er e m i n d e r
e-mails at one-to two-week intervals. After excluding
those who were unreachable (n = 18), defined as four
auto-generated ‘out of office’ replies, the final sample
was 1,109.
Survey Design and Content
Our survey obtained information about an investigator’s
experience with situations related to fCOI that could
introduce bias into a trial. The questionnaire content
was based on the International Committee of Medical
Journal Editors’ (ICMJE) uniform requirements for
manuscripts submitted to biomedical journals [11]; the
fCOI literature; and the input of our research team (see
Additional file 1). The ICMJE statement [11] was
expanded in 2008 [12]. These criteria have been widely
accepted by organizations including the World Associa-
tion of Medical Editors (WAME) [15] and Consolidated
Standards of Reporting Trials (CONSORT) [16]
Given that trials often take from four to eight years to
conduct and publish, we asked investigators to describe
their experiences over a five year time frame (2001-
2006). We collected information about situations that
could introduce bias during the stages of trial prepara-
tion (review of contracts and budgets, confidentiality
clauses, trial registration), conduct (trial design, data
access and ownership, data analysis and interpretation)
and dissemination (manuscript preparation and publica-
tion). For each situation we identified what we consid-
ered to be preferred practice to protect an investigator’s
independence and to avoid the introduction of bias.
Table 1 lists the preferred practices to promote the
objectivity of research and the rationale for their
inclusion.
Personal Experiences with fCOI
We asked investigators if they had ever experienced
fCOI or witnessed a situation involving fCOI. If so, they
were asked to describe the situation and whether these
experiences took place in the context of an industry or
non-industry funded trial.
Statistical analysis
We used descriptive statistics to characterize respon-
dents and their trial experience. Survey data were aggre-
gated anonymously.
Our main study outcome was the percentage of inves-
tigators that reported full adherence to each preferred
practice in all of their trials conducted from 2001-2006.
Free text comments provided by investigators about
their own personal or witnessed experiences with fCOI
were summarized into thematic areas by two authors
(SRK and WW). The initial agreement on the thematic
areas was 91% for investigators’ own experiences and
97% for experiences witnessed in a colleague. All differ-
ences were resolved by consensus.
Results
Of 1,109 eligible investigators at Canadian sites, 844
(76%) responded. Among responders, 76 (7%) declined
participation and 36 (3%) answered only the preliminary
administrative questions. 732 investigators (included
response rate, 66%) were in our final analysis. Of these,
32 did not provide information related to clinical trial
experience but provided responses related to personal
experiences with fCOI.
Almost all of the 732 investigators held primary uni-
versity appointments. 67% had over five years of trial
experience, and 64% had been the overall principal
investigator for at least one trial (Table 2). More than
80% of investigators had participated in multi-site trials.
Approximately half (n = 406) had been investigators on
trials funded by both industry and non-industry sources.
Preferred Practices
700 investigators provided data about adherence to the
practices designed to promote the objectivity of research
in their non-industry (n = 646 investigators) and indus-
try (n = 460) funded trials (Table 3).
Overall, in the trial preparation stage, 458 (65%) inves-
tigators had a signed contract for one or more trials. Of
these, 374 (82%) investigators reported always having
the contracts reviewed by the research ethics board
(REB) or institution and 54 (12%) reported no restrictive
confidentiality clauses within the contract. 523 (75%)
reported always having their budgets reviewed by their
REB or institution, and 274 (39%) reported always hav-
ing their trials registered (since 2005). For these 4 prac-
tices, full adherence was similar between industry and
non-industry trials.
In the trial conduct stage, less than half of investiga-
tors reported full adherence to preferred practices in all
of their trials with regards to data ownership (37%); data
access (38%); control over study design (35%); data
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dissemination stage, 368 (53%) investigators reported
always having ultimate control over the contents of sub-
mitted manuscripts and 450 (64%) reported an absence
of ghost authorship in all their manuscripts. In addition
to these reports of full adherence to preferred practice,
other investigators reported following these preferred
practices in some trials, but not all trials. Full adherence
to preferred practices in the trial conduct and dissemi-
nation stages was generally higher for non-industry rela-
tive to industry funded trials.
We also stratified investigators according to whether
they had experience in only a single funding environ-
ment or in both industry and non-industry funding
environments and compared the frequency of preferred
practices between industry and non-industry funded
trials within these strata. We found no differences in the
overall pattern of responses in either stratum. These
results are not reported here but are available in Addi-
tional file 2.
Personal Experience with fCOI
Overall, 269 (37%) investigators reported having person-
ally experienced or witnessed a situation involving fCOI
(Table 4). These experiences were personal (n = 33),
witnessed in a colleague (n = 184), or both (n = 52). Of
85 investigators who personally experienced a fCOI
situation, the most frequent theme was related to
recruitment (33%). Another theme involved study con-
duct (24%). 61 (72%) indicated that these fCOI experi-
ences involved industry-funded trials.
Of 236 investigators who reported witnessing a fCOI
situation in a colleague’s research, the most frequent
theme related to personal financial incentives (24%)
(Table 4). 180 (76%) of respondents indicated that the
situations they witnessed were in relation to industry-
funded trials.
Discussion
To our knowledge, our study is the first to obtain infor-
mation directly from investigators about practices
related to fCOI that may introduce bias into a trial at
the preparation, conduct, and dissemination stages. Pre-
vious studies have largely relied on information obtained
from indirect sources. For example, information on
restrictive confidentiality clauses has come from surveys
of medical school research administrators [17] while
information on investigator participation in trial design,
data access, and publications has come from surveys of
medical schools officials [18]. Court documents have
been the source of information for much of what we
know about the practice of ghost authorship [19-23]
Our findings suggest that full adherence to preferred
practice was highest when these practices are required
and enforced by an external agent. Specifically, three
Table 1 Survey questions related to preferred practices to promote the objectivity of research and their rationale
Practice Rationale
Signed contracts reviewed by institution [18] Reduce the risk of transparency
bias
Signed contracts do not have restrictive confidentiality clauses that prevent disclosure of trial information without
permission from the funder [17,18,29]
Reduce the risk of publication
bias
Budgetary reviewed by a REB or institutional official [3] Reduce the risk of transparency
bias
Registration of a trial in a WHO approved registry since the requirement for trial registration in 2005 [10,30,31] Reduce the risk of publication
bias [32]
Investigators rather than funder should have data ownership [17,18,33] Reduce the risk of reporting
bias
Investigator should have access to data from all sites [11,12] Reduce the risk of reporting
bias
Funder should not control final decisions regarding
Study design [11,12] Reduce the risk of biased study
designs
Data analysis [11,12] Reduce the risk of biased
analyses
Data interpretation [11,12] Reduce the risk of biased
interpretation
Funder should not control final decision on content of submitted manuscripts [11,12] Reduce the risk of reporting
bias
There should be no ghost authorship [34] Reduce the risk of reporting
bias
The survey questions related to preferred practices to promote the objectivity of research were based on the identified sources and the input of our research
team.
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tracts and budgets were reviewed by an REB or an insti-
tutional official. Further, these practices were equally
likely to occur in industry and non-industry funded trials.
The high rate of compliance may reflect the requirement
of institutions to review contracts and vigilance that
ethics board members apply when they review studies
[24]. Adherence to trial registration was also similar for
industry and non-industry trials after 2005 (when regis-
tration became a precondition for publication in an
Table 2 Investigator characteristics and clinical trial experience
Characteristics Respondents (N = 732)
n (%)
Primary appointment
University or academic teaching hospital 684(93)
Non-academic community-based hospital 27(4)
Other (e.g. private practice, cancer centre, pharmaceutical) 21(3)
Type of clinical trial
Non-industry trials only 240(33)
Industry trials only 54(7)
Both non-industry and industry trials 406(55)
None 28(4)
Did not answer 4(1)
Number of years of experience in clinical trials
≤ 5 192(26)
>5 489(67)
Not applicable 28(4)
Did not answer 23(3)
Most senior role in clinical trial
Principal investigator for entire trial -(trial PI) 466(64)
Principal investigator for site, No overall PI experience- (site PI) 177(24)
Other (No PI or site-PI experience) 56(8)
Did not answer 33(5)
Intervention(s) studied *
Drug therapy 552(75)
Device/equipment 217(30)
Diagnostic tests 174(24)
Surgery/procedure 151(21)
Education/counselling 139(19)
Management policy (e.g. specific thresholds for transfusion) 89(12)
Complementary and alternative medicine 78(11)
Psychotherapy 37(5)
Other (e.g. exercise, nutrition, radiation) 113(15)
Trial sites
Single 94(13)
Multiple 252(34)
Both (single and multiple) 353(48)
Did not answer 33(5)
Conflict of interest exposure
Any 269(37)
Personal only 33(5)
Witness of colleague 184(25)
Both personal and witness of colleague 52(7)
None 402(55)
Did not answer 61(8)
Note:
* The sum of response options is greater than 100% because survey respondents may have investigated more than one intervention type in different trials.
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Practices Trial Funding
Overall Non-
industry
Industry Adherence to preferred practice (Non-industry
vs. Industry)
(N =
700)
(N = 646)
*
(N =
460)
†
n(%) n(%) n(%)
Trial Preparation Stage
Signed contracts reviewed by institution
‡
Signed contracts 458 262 376
No trials 13(3) 10(4) 10(3)
Some trials 39(9) 21(8) 18(5)
All trials
§ 374(82) 191(73) 330(88) Similar
Not sure 22(5) 32(12) 12(3)
Did not answer 10(2) 8(3) 6(2)
Signed contracts have restrictive confidentiality
clauses
‡
Signed contracts 458 262 376
No trials
§ 54(12) 48(18) 28(7) Similar
Some trials 99(22) 35(13) 58(15)
All trials 201(44) 77(29) 212(56)
Not sure 94(21) 94(36) 72(19)
Did not answer 10(2) 8(3) 6(2)
Budgetary reviewed by a research ethics board or
institution official
No trials 39(6) 49(8) 22(5)
Some trials 92(13) 56(9) 28(6)
All trials
§ 523(75) 487(75) 386(84) Similar
Not sure 28(4) 38(6) 18(4)
Did not answer 18(3) 16(2) 6(1)
Trials registered in trial registry since 2005
No trials 50(7) 56(9) 36(8)
Some trials 221(32) 173(27) 69(15)
All trials
§ 274(39) 254(39) 141(31) Similar
Not sure 140(20) 138(21) 193(42)
Did not answer 15(2) 25(4) 21(5)
Trial Conduct Stage
Funder owns study data
No trials
§ 258(37) 394(61) 52(11) Higher in non-industry
Some trials 221(32) 42(7) 114(25)
All trials 107(15) 68(11) 172(37)
Not sure 87(12) 119(18) 114(25)
Did not answer 27(4) 23(3) 8(2)
Investigator has access to data from all sites
No trials 80(11) 69(11) 61(13)
Some trials 191(27) 94(15) 108(23)
All trials
§ 265(38) 306(47) 99(22) Higher in non-industry
Not sure 132(19) 147(23) 181(39)
Did not answer 32(5) 30(5) 11(2)
Funder controls final decisions regarding:
Study design
No trials
§ 247(35) 366(57) 78(17) Higher in non-industry
Some trials 228(33) 46(7) 112(24)
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requirement for all trials of interventions receiving regu-
latory approval in the United States since 2007 [10] and
has been included in the World Medical Association
Declaration of Helsinki since 2008 [25].
We found that adherence was lowest for preferred
practices outlined by ICMJE regarding trial conduct and
dissemination. There are a number of possible explana-
tions for this result. First, these practices are recom-
mended but not required by all medical journals.
Second, the ICMJE recommendations generally target
disclosure of information at the publication stage of the
trial. Guidance introduced earlier in the process would
alert investigators to preferred practices and encourage
their incorporation into the study design. A fCOI
Checklist [26] aimed at prospectively identifying investi-
gator fCOI in trials has been recently developed. To
facilitate the conduct of preferred practices throughout
the course of a clinical trial, this fCOI Checklist is
intended to be initiated during the trial preparation
stage and continues through to the trial’s result dissemi-
nation stage [26].
Our data are consistent with previous evidence that a
substantial proportion of trials have ghost authorship
[19,21,22]. Less than a third of surveyed individuals indi-
cated that ghost authorship was absent in all of their
industry sponsored trials experience compared to more
than two thirds for non-industry trials. A coordinated
oversight strategy has been proposed to address this
problem [19]. Increased awareness of this issue is
Table 3 Adherence to the 11 preferred practices stratified by trial stage and funding (Continued)
All trials 141(20) 118(18) 179(39)
Not sure 63(9) 98(15) 84(18)
Did not answer 21(3) 18(3) 7(2)
Data analysis
No trials
§ 276(39) 397(61) 92(20) Higher in non-industry
Some trials 222(32) 37(6) 114(25)
All trials 120(17) 109(17) 155(34)
Not sure 61(9) 85(13) 92(20)
Did not answer 21(3) 18(3) 7(2)
Data interpretation
No trials
§ 300(43) 404(63) 103(22) Higher in non-industry
Some trials 207(30) 36(6) 111(24)
All trials 106(15) 106(16) 126(27)
Not sure 66(9) 82(13) 113(25)
Did not answer 21(3) 18(3) 7(2)
Trial Dissemination Stage
Funder controls final decision on content of submitted
manuscripts
No trials
§ 368(53) 445(69) 124(27) Higher in non-industry
Some trials 168(24) 37(6) 100(22)
All trials 49(7) 41(6) 70(15)
Not sure 88(13) 100(15) 157(34)
Did not answer 27(4) 23(4) 9(2)
Completed manuscripts has ghost authorship
No trials
§ 450(64) 478(74) 147(32) Higher in non-industry
Some trials 100(14) 35(5) 75(16)
All trials 5(1) 4(1) 8(2)
Not sure 117(17) 104(16) 220(48)
Did not answer 28(4) 25(4) 10(2)
Notes:
* 646 investigators included 406 who had experience in both industry funding and non-industry funding trials and 240 who only had experience in non-industry
funding trials. We defined non-industry funding as support from a government agency, hospital, university, or other non-profit source (e.g., a federal granting
organization) and industry funding as support from a private for-profit corporation (e.g., pharmaceutical company).
† 460 investigators included 406 who had experience in both industry funding and non-industry funding trials and 54 who only had experience in industry
funding trials.
‡ Question was related to 458 investigators who had signed contracts.
§ Rows indicated the proportion of investigators that reported full adherence to the specific preferred trial practice in all of their trials experience.
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bias introduced by ghost authors.
Our findings are robust given that our original survey
was worded so that investigators responded without expli-
cit knowledge of the preferred behaviour. Additionally,
identical questions were used to capture industry and
non-industry funded trial experience. Our large number of
respondents and reasonable response rate indicates the
willingness of investigators to discuss potentially sensitive
issues concerning their experiences. Our findings also
describe the experiences of individual investigators. More
than a third reported having personally experienced or
witnessed a situation of potential fCOI, mostly in indus-
try-funded trials. One of the most frequently described
situations related to recruitment pressures. Our study indi-
cates the need to explore this issue further.
Limitations
First, our sample of Canadian investigators may not
reflect the perspectives of investigators globally. Increas-
ingly, clinical research sites are moving to areas such as
Eastern Europe and Latin America that may have less
experience with clinical trials [27]. Second, our sample
included only registered clinical trials. Since, registration
h a sb e e nap r e c o n d i t i o nf o rp u b l i c a t i o ni na nI C M J E
journal since 2005 [13] the trials included in our sample
may have been of higher quality than trials that were not
registered. Some of the trials included in our sample pre-
date the mandatory registration period. Third, response
bias is a concern, particularly when addressing potentially
sensitive issues involving fCOI. Our guarantee of anon-
ymity, and user-friendly questions helped to encourage
disclosure of useful information. The response rate to
our email survey was 76% with 66% useable responses.
We have no information from non-responders and there-
fore are unable to describe these individuals. Further, our
main study outcome was full adherence to preferred
practice in all of their trials experiences within 5-years of
our survey. We recognize that other surveyed investiga-
tors followed the preferred practices in some but not all
trials. Finally, we surveyed investigators about their trial
experience prior to 2007. Since we aimed to capture
practices across all stages of clinical trial conduct and
study result dissemination (average 4 to 8 years from
inception to completion [28]), we needed to allow suffi-
cient time for publication. Our results may not fully
reflect current practices but they provide a baseline from
which future studies can build.
Conclusions
Full adherence to practices designed to promote the
objectivity of research varied across trial stages and was
low overall, particularly for industry funded trials.
Adherence to preferred practices was highest when they
were required by an external agent. Guidance intro-
duced early in the trial process could alert investigators
to preferred practices and encourage their incorporation
into the study design.
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